The effect of neoadjuvant imatinib therapy on outcome and survival in rectal gastrointestinal stromal tumors: A multiinstitutional study

2021 ◽  
Author(s):  
Wenchang Yang ◽  
Qian Liu ◽  
Guole Lin ◽  
Bo Zhang ◽  
Hui Cao ◽  
...  
Keyword(s):  
Gastrointestinal Stromal Tumors ◽  
Imatinib Therapy ◽  
Stromal Tumors

Neoadjuvant imatinib therapy in rectal gastrointestinal stromal tumors

Surgery Today ◽  
2018 ◽  
Vol 49 (6) ◽  
pp. 460-466 ◽  
Author(s):  
Manabu Kaneko ◽  
Shigenobu Emoto ◽  
Koji Murono ◽  
Hirofumi Sonoda ◽  
Masaya Hiyoshi ◽  
...  
Keyword(s):  
Gastrointestinal Stromal Tumors ◽  
Imatinib Therapy ◽  
Stromal Tumors

scholarly journals Serum miRNA abundances discriminate imatinib-naive patients with advanced gastrointestinal stromal tumors (GIST) from those in remission on Imatinib therapy

2017 ◽  
Vol 28 ◽  
pp. v535
Author(s):  
H. Kosela Paterczyk ◽  
A. Paziewska ◽  
M. Kulecka ◽  
J. Karczmarski ◽  
M. Dabrowska ◽  
...  
Keyword(s):  
Gastrointestinal Stromal Tumors ◽  
Imatinib Therapy ◽  
Stromal Tumors ◽  
Serum Mirna

Local excision with adjuvant imatinib therapy for anorectal gastrointestinal stromal tumors

2013 ◽  
Vol 17 (5) ◽  
pp. 571-574 ◽  
Author(s):  
D. Centonze ◽  
E. Pulvirenti ◽  
A. Pulvirenti D’Urso ◽  
S. Franco ◽  
N. Cinardi ◽  
...  
Keyword(s):  
Local Excision ◽  
Gastrointestinal Stromal Tumors ◽  
Imatinib Therapy ◽  
Adjuvant Imatinib ◽  
Stromal Tumors

Adherence to imatinib therapy in gastrointestinal stromal tumors and chronic myeloid leukemia

2013 ◽  
Vol 21 (8) ◽  
pp. 2351-2357 ◽  
Author(s):  
Jasem Al-Barrak ◽  
Winson Y. Cheung
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Gastrointestinal Stromal Tumors ◽  
Myeloid Leukemia ◽  
Imatinib Therapy ◽  
Stromal Tumors

scholarly journals Management of a Gastrobronchial Fistula Connected to the Skin in a Giant Extragastric Stromal Tumor

2015 ◽  
Vol 2015 ◽  
pp. 1-5
Author(s):  
Emilio Muñoz ◽  
Fernando Pardo-Aranda ◽  
Noelia Puértolas ◽  
Itziar Larrañaga ◽  
Judith Camps ◽  
...  
Keyword(s):  
Case Report ◽  
Gastrointestinal Bleeding ◽  
Gastrointestinal Stromal Tumors ◽  
Stromal Tumor ◽  
Imatinib Therapy ◽  
Stromal Tumors ◽  
Gastrobronchial Fistula ◽  
Massive Gastrointestinal Bleeding ◽  
Life Threatening ◽  
Gastric Stromal Tumor

Introduction. Gastrointestinal stromal tumors first treatment should be surgical resection, but when metastases are diagnosed or the tumor is unresectable, imatinib must be the first option. This treatment could induce some serious complications difficult to resolve.Case Report. We present a 47-year-old black man with a giant unresectable gastric stromal tumor under imatinib therapy who presented serious complications such as massive gastrointestinal bleeding and a gastrobronchial fistula connected with the skin, successfully treated by surgery and gastroscopy.Discussion. Complications due to imatinib therapy can result in life threatening. They represent a challenge for surgeons and digestologists; creative strategies are needed in order to resolve them.

scholarly journals Optimizing Surgical and Imatinib Therapy for the Treatment of Gastrointestinal Stromal Tumors

2013 ◽  
Vol 17 (11) ◽  
pp. 1997-2006 ◽  
Author(s):  
Jason K. Sicklick ◽  
Nicole E. Lopez
Keyword(s):  
Gastrointestinal Stromal Tumors ◽  
Imatinib Therapy ◽  
Stromal Tumors

scholarly journals Macrophages and CD8+ T Cells Mediate the Antitumor Efficacy of Combined CD40 Ligation and Imatinib Therapy in Gastrointestinal Stromal Tumors

2018 ◽  
Vol 6 (4) ◽  
pp. 434-447 ◽  
Author(s):  
Jennifer Q. Zhang ◽  
Shan Zeng ◽  
Gerardo A. Vitiello ◽  
Adrian M. Seifert ◽  
Benjamin D. Medina ◽  
...  
Keyword(s):  
T Cells ◽  
Cd8 T Cells ◽  
Gastrointestinal Stromal Tumors ◽  
Imatinib Therapy ◽  
Antitumor Efficacy ◽  
Cd40 Ligation ◽  
Stromal Tumors

scholarly journals Prospective Observational Study of Imatinib Therapy in Japanese Patients with Advanced Gastrointestinal Stromal Tumors: Long-term Follow-up and Second Malignancy

2012 ◽  
Vol 42 (7) ◽  
pp. 578-585 ◽  
Author(s):  
Tatsuo Kanda ◽  
Takashi Ishikawa ◽  
Seiichi Hirota ◽  
Kazuhito Yajima ◽  
Shin-ichi Kosugi ◽  
...  
Keyword(s):  
Observational Study ◽  
Gastrointestinal Stromal Tumors ◽  
Prospective Observational Study ◽  
Japanese Patients ◽  
Imatinib Therapy ◽  
Long Term Results ◽  
Second Malignancies ◽  
Stromal Tumors

Abstract Objective Limited data are available concerning long-term results of imatinib therapy in patients with advanced gastrointestinal stromal tumors. We aimed to clarify the long-term outcomes of imatinib therapy in Japanese patients with advanced gastrointestinal stromal tumors. Methods A prospective, observational study of imatinib therapy for unresectable and metastatic gastrointestinal stromal tumors was conducted in our institution. Imatinib was initiated at a dose of 400 mg daily and continued until disease progression. Safety, efficacy and long-term tolerability and survival were evaluated in an intent-to-treat population. The median follow-up period in this study was 68 months. Results Seventy patients were enrolled between December 2001 and December 2009. Treatment-related Grade 3/4 adverse events occurred in 49 patients (70.0%). Although 14 patients required adverse effect management with hospitalization, only 5 patients (7.1%) withdrew from the treatment owing to imatinib intolerance. The tumor response and clinical benefit rates were 61.4 and 85.7%, respectively. Thirty-seven patients (52.9%) maintained the treatment at 400 mg daily imatinib, whereas 33 patients (47.1%) had their dose reduced to 300 mg daily or less. The overall survival rate at 5 years was 60.9% and the median survival time was 70 months. The median progression-free survival time of all the 70 enrolled patients was 30 months. Seven patients (10.0%) suffered from second malignancies, including three patients with genitourinary carcinomas. Conclusions Despite the need for dose reduction, the long-term results of imatinib therapy for advanced gastrointestinal stromal tumors were good in Japanese patients. Physicians should pay attention to the occurrence of second malignancies during imatinib therapy for gastrointestinal stromal tumor patients.

Sign in / Sign up

Export Citation Format

Share Document